ADVFN - Advanced Financial Network.
HOME» NASDAQ » L » DDSS Stock Price » DDSS Stock News

Labopharm Inc. Share News

 Labopharm Inc. (mm) Stock Price
DDSS Stock Price
 Labopharm Inc. (mm) Stock Chart
DDSS Stock Chart
 Labopharm Inc. (mm) Stock News
DDSS Stock News
 Labopharm Inc. (mm) Company Information
DDSS Company Information
 Labopharm Inc. (mm) Stock Trades
DDSS Stock Trades

Labopharm Gets FDA Approval For Once-Daily Trazodone Drug

DOW JONES NEWSWIRES Labopharm Inc. (DDSS) has received U.S. Food and Drug Administration approval for its once-daily formulation of the antidepressant trazodone for adults. The FDA had been expected to make an approval decision by Feb. 11. Labopharm's OLEPTRO Extended Release Tablets have been approved for the treatment of major depressive disorder in adults. The Canadian specialty-pharma company said it's actively exploring several alternatives for the U.S. commercialization of OLEPTRO and expects the drug to be available for prescription in the U.S. later this year. Labopharm said it will conduct a post-approval pediatric study. The FDA has asked it to provide data from a long-term maintenance study and an additional in-vitro alcohol dissolution study. On Nasdaq Tuesday, Labopharm closed at $2.61, down 1.9%. In pre-market trading Wednesday, it's up about 15%. -By Judy McKinnon, Dow Jones Newswires; 416-306-2100; judy.mckinnon@dowjones.com

Stock News for Labopharm Inc. (DDSS)
DateTimeHeadline
02/03/201008:24:00Labopharm Gets FDA Approval For Once-Daily Trazodone Drug

Labopharm Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad